This story is part of STAT’s quarterly series Something Ventured, which looks at early-stage startups. You can read the earlier stories in the series here.
Private biotech companies tend to be, well, private. That might explain why so many barely make a public peep after raising millions of dollars from venture capital firms. Few early-stage biotech companies in the Boston area issue more than a handful of press releases every year.